Question 1

What is Relmada Therapeutics's EV/EBITDA ratio?

Accepted Answer

Relmada Therapeutics (RLMD) EV/EBITDA ratio is currently not available. When EBITDA is negative, EV/EBITDA is reported as N/A. EV/Sales is the standard substitute for early-stage or temporarily loss-making companies.

Question 2

How is the EV/EBITDA ratio calculated?

Accepted Answer

EV/EBITDA = Enterprise Value ÷ Trailing Twelve-Month (TTM) EBITDA, where Enterprise Value = Market Capitalisation + Total Debt − Cash & Short-Term Investments. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the EV/EBITDA ratio?

Accepted Answer

The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.

Question 4

What is a good EV/EBITDA ratio for Relmada Therapeutics?

Accepted Answer

Mature, cash-generative businesses commonly trade in the 8–12× EV/EBITDA range; higher-growth, asset-light companies often trade at 15–25×+. EV/EBITDA is most useful for comparing companies with different capital structures (debt levels) or tax regimes. For Relmada Therapeutics specifically, the relevant sector benchmark is the current sector median of 15.1×.

Question 5

What is Relmada Therapeutics's historical EV/EBITDA ratio range?

Accepted Answer

In the available daily series, Relmada Therapeutics (RLMD) EV/EBITDA ratio has ranged from a low of -22.3× in 2015 to a high of -0.7× in 2015.

Question 6

What was Relmada Therapeutics's EV/EBITDA ratio in 2015?

Accepted Answer

Relmada Therapeutics (RLMD) EV/EBITDA ratio at the end of 2015 was -22.3×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month EBITDA figure available at that date.

Question 7

Why does Relmada Therapeutics's EV/EBITDA ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (enterprise value, which tracks share price plus net debt) and the denominator (EBITDA). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 8

Why is Relmada Therapeutics's EV/EBITDA ratio not available?

Accepted Answer

When EBITDA is negative, EV/EBITDA is reported as N/A. EV/Sales is the standard substitute for early-stage or temporarily loss-making companies.


2025	$329.67M	−$59.10M	—	—	Dec 31, 2025
2024	$15.69M	−$22.99M	—	—	Dec 31, 2024
2023	$31.00M	−$76.87M	—	—	Dec 31, 2023
2022	$26.26M	−$161.25M	—	—	Dec 31, 2022
2021	$86.06M	−$125.70M	—	—	Dec 31, 2021
2020	$104.25M	−$61.37M	—	—	Dec 31, 2020
2019	$88.68M	−$15.09M	—	—	Dec 31, 2019
2018	$5.88M	−$10.62M	—	—	Dec 31, 2018
2017	$1.88M	−$6.46M	—	—	Dec 31, 2017
2016	$2.62M	−$8.91M	—	—	Dec 31, 2016
2015	$5.71M	$418.00K	-22.3×	—	Dec 31, 2015
2014	$31.47M	−$40.36M	—	—	Dec 31, 2014
2013	$17.10M	−$50.19K	—	—	Nov 30, 2013
2012	$17.10M	−$20.26K	—	—	Nov 30, 2012


Gilead Sciences (GILD)	13.9×
Labcorp Holdings (LH)	13.6×
Amgen (AMGN)	13.6×
Charles River (CRL)	13.2×
Regeneron Pharmaceuticals (REGN)	12.9×
GE HealthCare (GEHC)	12.9×
UnitedHealth Group (UNH)	12.7×
Pfizer (PFE)	12.4×
Henry Schein (HSIC)	12.0×
Medtronic (MDT)	11.7×
AptarGroup (ATR)	11.5×
Bristol-Myers Squibb (BMY)	11.5×
Zimmer Biomet Holdings (ZBH)	11.2×
Biogen (BIIB)	10.5×
HCA Healthcare (HCA)	10.0×
Molina Healthcare (MOH)	8.8×
DaVita (DVA)	8.5×
IQVIA (IQV)	8.2×
Incyte (INCY)	7.9×
Cigna (CI)	7.8×
Elevance Health (ELV)	6.8×
Novo Nordisk (NVO)	6.5×
Solventum (SOLV)	5.8×
Universal Health Services (UHS)	5.7×
Humana (HUM)	4.5×

EV/EBITDA for Relmada Therapeutics (RLMD)

EV/EBITDA daily chart for Relmada Therapeutics (RLMD)

Historical EV/EBITDA for Relmada Therapeutics (RLMD) from 2012 to 2025

About EV/EBITDA at Relmada Therapeutics (RLMD)

Relmada Therapeutics EV/EBITDA by Year

Relmada Therapeutics EV/EBITDA 2015: -22.3×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

Relmada Therapeutics (RLMD) Key Financials

EV/EBITDA daily chart for Relmada Therapeutics (RLMD)

Historical EV/EBITDA for Relmada Therapeutics (RLMD) from 2012 to 2025

About EV/EBITDA at Relmada Therapeutics (RLMD)

Relmada Therapeutics EV/EBITDA by Year

Relmada Therapeutics EV/EBITDA 2015: -22.3×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

+What is Relmada Therapeutics's EV/EBITDA ratio?

+How is the EV/EBITDA ratio calculated?

+What is the EV/EBITDA ratio?

+What is a good EV/EBITDA ratio for Relmada Therapeutics?

+What is Relmada Therapeutics's historical EV/EBITDA ratio range?

+What was Relmada Therapeutics's EV/EBITDA ratio in 2015?

+Why does Relmada Therapeutics's EV/EBITDA ratio change over time?

+Why is Relmada Therapeutics's EV/EBITDA ratio not available?

Relmada Therapeutics (RLMD) Key Financials